The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR/ARHP Annual Meeting: Novel Approaches for Intra-Articular Arthritis Therapy

2015 ACR/ARHP Annual Meeting: Novel Approaches for Intra-Articular Arthritis Therapy

April 14, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Nanotubes can penetrate the dense cartilage extracellular matrix, translocate into the cytoplasm of the chondrocytes and deliver mASO, and have staying power.

Nanotubes can penetrate the dense cartilage extracellular matrix, translocate into the cytoplasm of the chondrocytes and deliver mASO, and have staying power.
Forance/shutterstock.com

SAN FRANCISCO—Penetrating the dense extracellular matrix of cartilage is a challenge for administering osteoarthritis drugs, but an answer might lie in the matrix itself—in particular, its electrical charge, researchers reported at the 2015 ACR/ARHP Annual Meeting.

You Might Also Like
  • 2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • 2015 ACR/ARHP Annual Meeting: How Gender Differences Affect Pain
Explore This Issue
April 2016
Also By This Author
  • How to Diagnose Shoulder Pain

Electrical Affinity

Investigators at the Massachusetts Institute of Technology have found—at least in vitro and in animals—that delivering drugs on particles with an electrical affinity for this extracellular matrix (ECM) appears to overcome these barriers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In cartilage ECM, aggrecan aggregate forms a kind of gel that fills up the spaces between collagen fibrils, said Alan Grodzinsky, ScD, professor of biological, electrical and mechanical engineering at MIT, who led the research.

“Any therapeutic that you’re trying to get to the cell or [to deliver] intra-cellularly has to wind its way through this matrix,” he said. “It’s very tough to get through.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Intra-articular administration of the drug alone is not good enough; the drugs clear out of the joint space too quickly to have the intended effect.

But by using so-called charged nano-carriers, drugs can be delivered with rapid penetration and then bind to the ECM inside the cartilage. When that happens, Dr. Grodzinsky said, “the matrix becomes an intra-tissue depot delivery system rather than hindering transport into the tissue.”

Research carried out by Post-Doctoral Associate Ambika Bajpayee, PhD, turned to avidin, a protein with a high positive charge—attractive due to its size and because of the high negative charge of cartilage extracellular matrix.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In vitro studies showed that avidin had an uptake that was 400 times higher than its neutral counterpart, NeutrAvidin, in bovine cartilage as thick as human cartilage, and that more than 90% of the avidin that was absorbed remained in the cartilage for at least 15 days.1

‘There is still much room for improvement with the use of nanoparticles in drug delivery—particularly by specifically identifying ligands & receptors that could help promote particle & drug transport.’ —Dr. Bottini

“The avidin that was present upstream of the cartilage got sucked right in,” Dr. Grodzinsky said.

Subsequent case studies on rats and rabbits showed deep penetration and demonstrated the importance of cartilage thickness in retention of the particles.2,3

“Once you’ve loaded this material inside, due to electrostatic attraction, it leaves the cartilage at a rate that will depend on thickness,” he said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Osteoarthritis Tagged With: 2015 ACR/ARHP Annual Meeting, American College of Rheumatology, intra-articular arthritis, nano-carrier, nanotube, Osteoarthritis, Research, therapy, TreatmentIssue: April 2016

You Might Also Like:
  • 2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis
  • ACR/ARHP Annual Meeting 2012: New Research Into Stem Cell Therapy and Drugs May Lead to Breakthrough Treatments for Osteoarthritis
  • 2015 ACR/ARHP Annual Meeting: How Gender Differences Affect Pain
  • 2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.